Schwab Charles Investment Management Inc. Has $5.39 Million Holdings in Retrophin, Inc. (RTRX)

Schwab Charles Investment Management Inc. raised its stake in shares of Retrophin, Inc. (NASDAQ:RTRX) by 35.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 277,688 shares of the biopharmaceutical company’s stock after buying an additional 73,067 shares during the quarter. Schwab Charles Investment Management Inc. owned about 0.73% of Retrophin worth $5,385,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in RTRX. Weiss Multi Strategy Advisers LLC acquired a new stake in Retrophin during the 1st quarter valued at $185,000. Dynamic Technology Lab Private Ltd acquired a new stake in Retrophin during the 1st quarter valued at $219,000. Fox Run Management L.L.C. acquired a new stake in Retrophin during the 2nd quarter valued at $246,000. American International Group Inc. grew its holdings in Retrophin by 7.1% during the 1st quarter. American International Group Inc. now owns 22,300 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 1,475 shares during the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Retrophin by 12.8% during the 1st quarter. Wells Fargo & Company MN now owns 50,785 shares of the biopharmaceutical company’s stock valued at $938,000 after buying an additional 5,763 shares during the last quarter.

RTRX has been the topic of a number of analyst reports. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 24th. Finally, BMO Capital Markets reiterated a “buy” rating and set a $44.00 target price on shares of Retrophin in a report on Friday, October 6th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Retrophin presently has a consensus rating of “Buy” and an average price target of $36.00.

In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total transaction of $31,005.00. Following the transaction, the chief operating officer now directly owns 13,622 shares in the company, valued at approximately $306,495. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.41% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Schwab Charles Investment Management Inc. Has $5.39 Million Holdings in Retrophin, Inc. (RTRX)” was posted by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of US & international copyright and trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/2956557/schwab-charles-investment-management-inc-has-5-39-million-holdings-in-retrophin-inc-rtrx.html.

Shares of Retrophin, Inc. (NASDAQ:RTRX) opened at 24.265 on Friday. The firm’s market cap is $931.41 million. The firm’s 50-day moving average price is $24.05 and its 200-day moving average price is $20.29. Retrophin, Inc. has a one year low of $15.55 and a one year high of $25.44.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.10). The business had revenue of $38.80 million during the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The company’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 EPS. Equities research analysts expect that Retrophin, Inc. will post ($1.13) earnings per share for the current fiscal year.

Retrophin Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.